LIVE STATUS BOARD / BPC-157 + TB-500
BPC-157 TB-500 is the two-peptide Wolverine blend, with every repair claim graded against the literature.
Two constituents, two mechanisms, one repair signal. The single-compound findings are established; the combination has zero controlled trials on record. This board posts both, side by side.
What the BPC-157 TB-500 board reads
BPC-157 TB-500 is the research-community name for a two-peptide pairing: BPC-157, a 15-amino-acid pentadecapeptide derived from a human gastric-juice protein, run alongside TB-500, a synthetic Ac-LKKTETQ heptapeptide taken from the actin-binding region of Thymosin Beta-4 [1][3]. The blend is marketed and discussed as a tissue-repair "stack" under the name Wolverine. It is not a single chemical entity, not an approved product, and not a substance with a clinically validated composition or ratio.
This site grades the pairing the way a monitoring console grades a feed. The established readouts are green: a fully transected rat Achilles tendon healed across biomechanical, functional and microscopic measures under BPC-157 [1]; BPC-157 up-regulates VEGFR2 and drives angiogenesis through a VEGFR2-Akt-eNOS route [2]; a 2-angstrom crystal structure pinned down how Thymosin Beta-4 sequesters actin [3]. The amber readouts are preclinical: those findings are animal-model, in-vitro, and single-compound. The red readout is the one the blend cannot escape — there is no controlled human trial of BPC-157 and TB-500 given together, and no validated pharmacokinetics for the combination [9].
Every quantitative line below is cited to a study. Where the evidence is single-compound, the page says so; where it is blend-level, the grade reads NO-HUMAN-DATA.
BPC-157 and TB-500: What the Wolverine blend pairs
BPC-157 and TB-500 pair two molecules that act through largely non-overlapping pathways. BPC-157 (Body Protection Compound 157; sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight ~1419.5 Da) is the local cytoprotective and pro-angiogenic channel — it up-regulates VEGFR2, modulates the nitric-oxide system, and sensitizes growth-hormone-receptor signaling in tendon fibroblasts [2]. TB-500 (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, ~889 Da) is the cytoskeletal channel — its LKKTETQ motif binds monomeric G-actin one-to-one to regulate the actin dynamics that drive cell migration [3].
One caveat travels with the second channel. "TB-500" as sold is the 7-amino-acid fragment, but the bulk of the efficacy data attributed to it was generated with full-length Thymosin Beta-4 (~4963 Da), not the heptapeptide [4][5]. A consolidated review of Thymosin Beta-4 describes actin binding, cell mobilization, reduced scar-forming myofibroblasts, anti-inflammatory signaling and angiogenesis — the migration-and-repair half of the blend rationale [4]. The blend inherits that fragment-versus-protein gap.
BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to residues 17-23, the actin-binding motif, of Thymosin Beta-4 [3][5]. The Wolverine blend pairs the two.
What Is the Wolverine Peptide Blend?
The Wolverine peptide blend is a research-community construct, not a registered drug. It names a co-formulation of BPC-157 and TB-500 marketed and discussed as a regenerative "stack," with vials commonly labeled at a combined per-vial mass such as 10 mg BPC-157 plus 10 mg TB-500 [labels are unstandardized]. No standardized composition, no validated ratio, and no approved indication exist for it [9].
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack." It is not a single chemical entity or an approved product, and no standardized composition or ratio is clinically validated [9].
What is the blend used for in research?
In animal models the two constituents are studied separately for tissue repair: BPC-157 for tendon, ligament and muscle healing [1], and TB-500 / Thymosin Beta-4 for cell migration, wound re-epithelialization and angiogenesis [4]. The combination itself has no controlled study [6].
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid pentadecapeptide (~1419.5 Da) from a human gastric-juice protein, acting on VEGFR2/eNOS angiogenic and growth-hormone-receptor pathways [2]. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ, ~889 Da) of Thymosin Beta-4 that sequesters G-actin to regulate cell migration [3][5].
BPC 157 TB 500 (Unhyphenated)
BPC 157 TB 500 — written without hyphens — is the same pairing as BPC-157 TB-500. Search surfaces for the blend run in several spellings (hyphenated, unhyphenated, spelled-out, and the "BPC157 TB500" compaction); all point to the identical two constituents and the identical evidence base, which is single-compound and overwhelmingly preclinical [6]. The spelling does not change the readout: the established findings are for each peptide alone, and the combination has no human trial [9].
BPC-157 with TB-500: The combination rationale
The case for running BPC-157 with TB-500 is mechanistic complementarity. BPC-157 supplies a local angiogenic and cytoprotective signal (VEGFR2-Akt-eNOS), while TB-500 supplies an intracellular actin-sequestration signal that mobilizes migrating cells [2][3]. On paper, one peptide builds the vascular supply and the other moves the repair cells — two non-overlapping levers on the same process.
That reasoning is an extrapolation, not a result. No peer-reviewed study defines a synergy ratio, a combination dose, or a shared endpoint for the two given together, and a 2025 systematic review of BPC-157 spanning 36 studies makes no mention of TB-500 or any combination use [6]. The pairing is plausible and untested in the same breath. You can read the combination rationale and synergy claim in full on the research page.
BPC-157 with TB-500: the combination rationale
The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) while TB-500 supplies an intracellular actin-sequestration signal driving cell migration [2][3]. This "synergy" is a theoretical extrapolation from two non-overlapping mechanisms, not a finding from a controlled combination study [6].
Why are BPC-157 and TB-500 combined?
The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal while TB-500 supplies an intracellular actin-sequestration signal driving cell migration [2][3]. This synergy is a theoretical extrapolation from two non-overlapping mechanisms, not a finding from a controlled combination study [6].
BPC-157 TB-500 Stack (Wolverine)
"Stack" is the community term for running two compounds together, and the BPC-157 TB-500 stack is the most-discussed tissue-repair pairing in research-peptide forums. The label does not confer evidence. The constituent findings are real — see the BPC-157 and TB-500 tendon-repair research — but the stack itself remains unstudied as a unit, with no validated dose and no human safety dataset for the combination [9][8].
Wolverine Injection: Routes studied in research
In the research community the blend is handled predominantly by subcutaneous or intramuscular injection; the underlying rodent efficacy studies most often used intraperitoneal dosing [1][9]. None of these routes derives from a controlled human efficacy trial of the blend. This site describes routes as studied, not as instructions.
BPC-157 TB-500 Stack (Wolverine)
The BPC-157 TB-500 stack, known as Wolverine, pairs the two peptides as a tissue-repair combination. Its constituent evidence is single-compound and preclinical; the stack as a unit has no controlled trial, no validated ratio and no human safety data [6][9].